Dr. Reddy's Laboratories announced today that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy's - See more at: http://ways2capital-equitytips.blogspot.in/2016/03/dr-reddys-acquires-e7777s-rights-from.html#sthash.xu9xy51H.dpuf
Drugmaker Dr Reddy's Laboratories said it has signed a commercialisation deal with Australia's Hatchtech for the latter's prescription head lice product Xeglyze Lotion. - See more at: http://ways2capital-review.blogspot.in/2015/09/dr-reddys-signs-commercialisation-deal.html#sthash.HGFJaUwH.dpuf
Dr Reddy's Laboratories submitted a response to the US health regulator on a warning letter it had received last month. - See more at: http://ways2capital-equitytips.blogspot.in/2015/12/dr-reddys-submits-response-to-usfda-on.html#sthash.cHBBZ00E.dpuf
Get #Ledipasvir #Sofosbuvir Tablets marketed and distributed by Dr. Reddy's Laboratories Limited. Get #Resof L Tablets price which containing the same contents i.e., 90 mg Ledipasvir and 400 mg Sofosbuvir in each tablets under the packaging of 28 tablets in each pack. Dr. Reddy's India Ledipasvir Sofosbuvir Tablets highly recommended drug for the treatment of hepatitis C. Resof-L Tablets is approved for people with #genotype 1 hepatitis C virus (
Indian ADRs ended higher on Thursday. In the banking space, ICICI Bank was up 0.07 percent at USD 6.76. HDFC Bank added 0.11 percent at USD 57.83. In the IT space, Infosys was up 0.15 percent at USD 18.33. Wipro rose 0.14 percent at USD 12.16. In the other sectors, Tata Motors gained 0.09 percent at USD 27.13. Dr Reddy’s Laboratories shed 0.23 percent at USD 46.50.
Pharma major Dr Reddy's Laboratories is expected to report a 4.1 percent growth in first quarter net profit at Rs 573.09 crore year-on-year. - See more at: http://ways2capital-equitytips.blogspot.in/2015/07/dr-reddys-labs-q1-net-seen-up-4-us-biz.html#sthash.sn6Muf4s.dpuf
Dr Reddy’s Laboratories has proclaimed here nowadays that it's launched Docetaxel Injection USP twenty mg/ millilitre and eighty mg/ four millilitre, a therapeutic equivalent of generic version of TAXOTERA in North American country market. Dr Reddy’s ANDA is approved by the u. s. Food & Drug Administration (USFDA).